Before joining Enormous, Joy Chauhan was Managing Partner (North) and Chief Client Officer at JWT/Wunderman Thompson (now VML) ...

Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...

Elraglusib (9-ING-41) is a glycogen synthase kinase-3 beta (GSK-3β) inhibitor. The ongoing phase 1/2 Actuate-1902 trial ...

Vesalius Will Apply its Proprietary Platform to Identify Novel Intervention Points that GSK may Advance for the Treatment of Patients with Parkinson’s Disease GSK has Licensed a Preclinical Small ...

Though prescribing climate-friendly inhalers is environmentally sound, some experts warn certain patients may be overlooked.

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

CNW/ - GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...

Good morning, and welcome to the Wave Life Sciences Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen only mode. As a reminder, this call is being ...

Since 2017, Merck (known as MSD outside of the U.S. and Canada), GSK and Eisai have been partnering to donate Mectizan, albendazole, and DEC, respectively, to accelerate the elimination of LF in ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

The global artificial intelligence (AI) in drug discovery market is projected to reach USD 6.89 billion by 2029 from USD 1.86 billion in ...